Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

Next Previous
Search
Trial Profile

AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afuresertib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Ovarian cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AKTRES

Most Recent Events

  • 05 Dec 2014 Accrual to date is 66% according to United Kingdom Clinical Research Network record.
  • 06 Mar 2014 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
  • 07 Feb 2014 Accrual to date is 45% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top